{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04234997",
            "orgStudyIdInfo": {
                "id": "HSC-MS-19-0966"
            },
            "organization": {
                "fullName": "The University of Texas Health Science Center, Houston",
                "class": "OTHER"
            },
            "briefTitle": "Suvorexant to Reduce Symptoms of Nicotine Use",
            "officialTitle": "Suvorexant to Reduce Symptoms of Nicotine Use: A Double-blind, Placebo-controlled Study",
            "therapeuticArea": [
                "Other"
            ],
            "study": "suvorexant-to-reduce-symptoms-of-nicotine-use"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-08-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-09-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-09-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-01-15",
            "studyFirstSubmitQcDate": "2020-01-15",
            "studyFirstPostDateStruct": {
                "date": "2020-01-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-28",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Robert Suchting",
                "investigatorTitle": "Assistant Professor",
                "investigatorAffiliation": "The University of Texas Health Science Center, Houston"
            },
            "leadSponsor": {
                "name": "The University of Texas Health Science Center, Houston",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to assess the impact of suvorexant on established measures of smoking relapse risk (craving,withdrawal, stress reactivity, latency to self-administration) and to validate the somnolent effect of suvorexant on sleep metrics in a sample of individuals with tobacco use disorder"
        },
        "conditionsModule": {
            "conditions": [
                "Smoking Cessation"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Suvorexant 20 mg",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Suvorexant 20 mg"
                    ]
                },
                {
                    "label": "Suvorexant 0mg",
                    "type": "PLACEBO_COMPARATOR",
                    "interventionNames": [
                        "Drug: Suvorexant 0mg"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Suvorexant 20 mg",
                    "description": "Participants will be advised to take the medication at 10PM for 7 days.Participants will be instructed to stop smoking by 10 pm the day before, in order to ensure they meet the breath CO criterion (CO \u2264 4 ppm) indicating overnight abstinence.",
                    "armGroupLabels": [
                        "Suvorexant 20 mg"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Suvorexant 0mg",
                    "description": "Participants will be advised to take the medication at 10PM for 7 days.Participants will be instructed to stop smoking by 10 pm the day before, in order to ensure they meet the breath CO criterion (CO \u2264 4 ppm) indicating overnight abstinence.",
                    "armGroupLabels": [
                        "Suvorexant 0mg"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in craving as assessed by a Visual Analog Scale (VAS) for Craving",
                    "description": "The VAS scale ranges from 0(not at all) to 100(extreme craving);a higher score indicating a worse outcome",
                    "timeFrame": "Day1,Day8"
                },
                {
                    "measure": "Change in stress as assessed by a Visual Analog Scale (VAS) for Stress",
                    "description": "The VAS scale ranges from 0(not at all) to 10(extreme stress);a higher score indicating a worse outcome",
                    "timeFrame": "Day1,Day8"
                },
                {
                    "measure": "Change in Stress Reactivity as assessed by Heart Rate During the Cold Pressor Test (CPT)",
                    "timeFrame": "Day1,Day8"
                },
                {
                    "measure": "Change in Stress Reactivity as assessed by cortisol During the Cold Pressor Test (CPT)",
                    "timeFrame": "Day1,Day8"
                },
                {
                    "measure": "Change in smoking as Assessed by Latency to Self-Administration during the Smoking Relapse Assessment",
                    "timeFrame": "Day1,day8"
                },
                {
                    "measure": "Change in smoking as Assessed by Number of Self-Administrated Cigarettes during the Smoking Relapse Assessment",
                    "timeFrame": "Day1,day8"
                },
                {
                    "measure": "Change in sleep quality as assessed by the Garmin Vivosmart3 Actigraphy Device",
                    "description": "Quality defined as proportion of time in deep sleep",
                    "timeFrame": "Day1,day8"
                },
                {
                    "measure": "Change in sleep duration as assessed by the Garmin Vivosmart3 Actigraphy Device",
                    "description": "Duration as the total amount of time asleep",
                    "timeFrame": "Day1,day8"
                },
                {
                    "measure": "Change in sleep restlessness as assessed by the Garmin Vivosmart3 Actigraphy Device",
                    "description": "Restlessness as the number of times waking up during sleep",
                    "timeFrame": "Day1,day8"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in stress as assessed by the Depression-Anxiety-Stress 21 (DASS21) Self-Report Questionnaire - Stress Subscale",
                    "description": "The DASS 21 is a 21 item self report questionnaire. Each item is scored from 0 (did not apply to me at all over the last week) to 3 (applied to me very much or most of the time over the past week).",
                    "timeFrame": "Day1,day8"
                },
                {
                    "measure": "Change in stress as assessed by the Personal Stress Scale (PSS)",
                    "description": "There are 10 questions ranging from a score of 0(never) to 4(very often) for a total maximum score of 40",
                    "timeFrame": "Day1,day8"
                },
                {
                    "measure": "Change in stress reactivity as assessed by Systolic Blood Pressure During the Cold Pressor Test (CPT)",
                    "timeFrame": "Day1,day8"
                },
                {
                    "measure": "Change in stress reactivity as assessed by Diastolic Blood Pressure During the Cold Pressor Test (CPT)",
                    "timeFrame": "Day1,day8"
                },
                {
                    "measure": "Change in sleep quality as assessed by the Patient-Reported Outcomes Measurement Information System(PROMIS) Sleep Disturbance Short Form",
                    "description": "This scale ranges form 1(very much)to 5(not at all)",
                    "timeFrame": "Day1,day8"
                },
                {
                    "measure": "Change in sleep quality as assessed by the Epworth Sleepiness Scale (ESS)",
                    "description": "This scale ranges form 0(would never dose) to 3(high chance of dosing)",
                    "timeFrame": "Day1,day8"
                },
                {
                    "measure": "Change in Withdrawal Severity as Assessed by the Minnesota Nicotine Withdrawal Questionnaire (MNWQ)",
                    "description": "This scale contains 9 questions scored between 0-4 with higher scores meaning greater withdrawal symptoms",
                    "timeFrame": "Day1,day8"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* non-treatment seeking cigarette smokers that report smoking atleast 10 cigarettes per day\n\nExclusion Criteria:\n\n* greater than mild substance use disorder on drugs other than nicotine\n* a Diagnostic and Statistical Manual of Mental Disorders(DSM)-IV axis I psychiatric disorder or neurological disease or disorder requiring ongoing treatment and/or making study participation unsafe\n* significant current suicidal or homicidal ideation - medical conditions contraindicating administration of suvorexant (e.g., severe pulmonary disease, severe cardiovascular disease or clinically abnormal EEG, severe liver or kidney disease, seizure disorder, or sleep disorder - particularly narcolepsy)\n* taking medications known to have significant drug interactions with the study medication(s) (e.g., Monoamine oxidase inhibitors(MAO) inhibitors, anticonvulsants, haloperidol, phenothiazines, anesthetics, and all sedatives)\n* currently or recently (last 3 months) treated for substance use \\[other than nicotine\\] or another psychiatric condition\n* conditions of probation or parole requiring reports of drug use to officers of the court\n* impending incarceration\n* pregnant or nursing for female patients\n* inability to read, write, or speak English \\[required for lab tasks and psychometric scales\\]\n* unwillingness to sign a written informed consent form\n* subjects with alcohol use disorders or report recent problem drinking (5/4 drinks for males/females in \\< 2.5 hours or \\> 10 alcoholic drinks per week)\n* any illness,condition, or use of medications which in the opinion of the PI and/or admitting physician would preclude safe and/or successful completion of the study.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Robert Suchting, MD",
                    "role": "CONTACT",
                    "phone": "(713) 486-2521",
                    "email": "Robert.Suchting@uth.tmc.edu"
                },
                {
                    "name": "Jessica Vincent",
                    "role": "CONTACT",
                    "phone": "(713) 486-2645",
                    "email": "Jessica.N.Vincent@uth.tmc.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Robert Suchting, MD",
                    "affiliation": "The University of Texas Health Science Center, Houston",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "The University of Texas Health Science Center at Houston",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Robert Suchting, MD",
                            "role": "CONTACT",
                            "phone": "713-486-2521",
                            "email": "Robert.Suchting@uth.tmc.edu"
                        },
                        {
                            "name": "Jessica Vincent, MD",
                            "role": "CONTACT",
                            "phone": "(713) 486-2645",
                            "email": "Jessica.N.Vincent@uth.tmc.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000551624",
                    "term": "Suvorexant"
                }
            ],
            "ancestors": [
                {
                    "id": "D000068776",
                    "term": "Sleep Aids, Pharmaceutical"
                },
                {
                    "id": "D000006993",
                    "term": "Hypnotics and Sedatives"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000068796",
                    "term": "Orexin Receptor Antagonists"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12478",
                    "name": "Nicotine",
                    "relevance": "LOW"
                },
                {
                    "id": "M234494",
                    "name": "Suvorexant",
                    "asFound": "Botulinum Toxin A",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14268",
                    "name": "Promethazine",
                    "relevance": "LOW"
                },
                {
                    "id": "M7338",
                    "name": "Diphenhydramine",
                    "relevance": "LOW"
                },
                {
                    "id": "M10043",
                    "name": "Hypnotics and Sedatives",
                    "relevance": "LOW"
                },
                {
                    "id": "M307",
                    "name": "Orexin Receptor Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "AAll",
                    "name": "Anti-Allergic Agents"
                },
                {
                    "abbrev": "Derm",
                    "name": "Dermatologic Agents"
                },
                {
                    "abbrev": "AnEm",
                    "name": "Antiemetics"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                }
            ]
        }
    },
    "hasResults": false
}